ENV-308 / Enveda Biosci - LARVOL DELTA

Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise (Yahoo Finance) - "The Phase 1 study also measured the impact of ENV-308 on leptin, a hormone released by fat cells to control appetite by telling the brain how much energy the body has stored. In obesity, leptin levels are usually chronically elevated, and the brain stops responding to it, a state called leptin resistance. In animal models, ENV-308 showed rapid reductions in leptin levels, potentially consistent with improved leptin responsiveness and sensitivity. In the Phase 1 trial, the effect on circulating leptin levels was confirmed, with the largest reductions observed in people who had the highest leptin levels relative to their sex at baseline. Additional clinical studies are now planned to further characterize the effects of ENV-308 on leptin biology and function...Enveda plans to test in a Phase 2 trial the ability of ENV-308 to maintain weight loss and other metabolic benefits."

New P2 trial • P1 data • Obesity

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy (Businesswire) - "The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and early pharmacodynamic signals of ENV-308."

IND • Trial status • Obesity